



Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. *Nature Reviews Cancer*. (2007). Nov; 7(11): 834-46.

Aguirre-Ghiso JA. Opposing roles for mitogenic and stress signaling pathways in the regulation of cancer dormancy: a balancing act. *Metastasis*. Rinker-Schaeffer, Carrie (Ed.) ISBN: 978-1-60327-338-1. Not yet published. Available: June 3, (2008). (Book Chapter)

Asher, G., Dym, O., Tsvetkov, P., Adler J. and Shaul, Y (2006). The crystal structure of NQO1 in complex with its potent inhibitor dicoumarol. *Biochemistry*, 45(20):6372-6378.

Asher, G., Reuven, N. and Shaul, Y. (2006). 20S proteasomes and protein degradation by default. *BioEssay*. 28(8):844-849.

Baroni TE, Lastro MT, Ranganathan AC, Tenenbaum SA, Conklin DS, and Aguirre-Ghiso JA. Ribonimic and Short Hairpin RNA Gene Silencing Methods to Explore Functional Gene Programs Associated with Tumor Growth Arrest. *Cancer Genomics and Proteomics* (Humana Press) Fisher, Paul (Ed.). *Methods Mol Biol*. (2007); 383:227-44

Barrett AN, Gupta R, Glasow A, Grimwade D, von Lindern M, Waxman S, Mills K, Burnett A, Enver T, and Zelent A. Deregulation of RAR $\gamma$  and RAR $\gamma$ -Specific miRNAs in AML. *Blood* (ASH Annual Meeting Abstracts), 110:3182, 2007.

Blair, J. A. Rauh, D., Kung, C., Yun C-H., Fan, Q-W., Zhang, C., Eck, M. J., Weiss, W. A., and Shokat, K. M. (2007) Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. *Nature Chemical Biology*, 3: 229-238.

Buzzai M, Licht JD. New Molecular Concepts and Targets in Acute Myeloid Leukemia- *Current Opinion in Hematology*, 15:82-87, 2008. PMID :18300752

Caius G. Radu, Chengyi J. Shu, Evan Nair-Gill, Stephanie M. Shelly, Jorge R. Barrio, Nagichettiar Satyamurthy, Michael E. Phelps, and Owen N. Witte. CD4+CD25- T cells transduced to express MHC class I-restricted epitope specific TCR synthesize Th1 cytokines and exhibit MHC class-I-restricted cytolytic effector function in a human melanoma model. (*Journal of Immunology*, in press).

Chan, I., I.V. Lebedeva, Z.-Z. Su, D. Sarkar, K. Valerie and P.B. Fisher. Progression-elevated gene-3 promoter (PEGProm) confers cancer cell-selectivity to human polynucleotide phosphorylase (hPNPaseold-35)-mediated growth suppression. *J. Cell. Physiol*. in press, 2008. (PMID: 17960560).

Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN Nuclear Localization Is Regulated by Oxidative Stress and Mediates p53-Dependent Tumor Suppression. *Mol Cell Biol*. 2008 Mar 10; [Epub ahead of print].

Cheng, A, Ching Cheng, N., Ford, J., Smith, J., Murray, J., Flemming, C., Lastowska, M., Jackson, M., Hackett, C.S., Weiss, W. A., Evans, T., Marshall, G.M., Kees, U.R, Norris, M.D., and Haber, M. (2007) Cell lines from MYCN transgenic murine tumors reflect the molecular and biological characteristics of human neuroblastoma. *Eur J. Cancer*, 32: 1467-1475.

Chesler, L., Goldenberg, D., Seales, I., Satchi-Rainaro, R., Grimmer, M., Collins, R., Struett, C., Nguyen, K.M., Kim, G., Tihan, T., Bao, Y., Brekken, R.A., Bergers, G., Folkman, J., and Weiss, W.A. (2007) Blockade of angiogenesis leads to regression of established tumors in murine neuroblastoma driven by a TH-MYCN transgene. *Cancer Research*, 67:9435-9442.

Dan, H., M. Cooper, P. Cogswell, A. Duncan, J. Ting, and A. Baldwin (2008). Akt-dependent regulation of NF- $\kappa$ B requires mTOR/Raptor interaction with IKK. *Genes and Development*, provisionally accepted. Albert S. Baldwin

Dan, H., M. Adli, and A. Baldwin (2007). Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by IKKa. *Cancer Res.* 67, 6263-6269.

Da Silva GF, Ghetu A, Cerchietti L, Polo JM, Coop A, Privé GG, Mackerell A, Melnick A. A small molecule inhibitor of BCL6 kills human DLBCL cells in vitro and in vivo. 2008.

Delva L, Zelent A, Naoe T, Fenaux P, Waxman S, Degos L, Chomienne C. Meeting Report: The 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. *Cancer Res* 67:10635-10637, 2007.

Diaz Z, Laurenzana A, Mann KK, Schipper HM and WH Miller Jr. Trolox enhances the antitumor effects of  $As_2O_3$ , while protecting against liver toxicity. *Leukemia* 21:2117-2127, 2007.

Dragnev KH, Dmitrovsky E Cyclin degradation for cancer therapy and chemoprevention. *J Cell Biochem* 102:864-877, 2007.

Dragnev KH, Petty WJ, Shah SH, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, and Dmitrovsky E. A proof-of-principle bexarotene clinical trial in patients with non-small cell lung cancer. *Clinical Cancer Res* 13:1794-1800, 2007.

Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E. Uncovering novel targets for cancer chemoprevention. In: *Recent Results in Cancer Research* 174:235-243, 2007

Duncan, E., Goetz C, Stein S, Mayo K, Skaggs B, Ziegelbauer K, Sawyers C, and Baldwin A. (2008). IKK $\beta$  inhibition induces cell death in imatinib-resistant and T315I-dasatinib-resistant BCR-ABL+ cells. *Mol. Cancer Ther.* 7, 391-397.

Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. *Cancer Res.* 2006; 66:10513-6.

Emdad, L., I.V. Lebedeva, Z.-z. Su, P. Gupta, D. Sarkar, J. Settleman and P.B. Fisher. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. *J. Cell. Physiol.*, 210: 549-559, 2007. (PMID: 17111370).

Estrada Y, Dong J, Ossowski L. A positive cross talk between ERK and p38 in melanoma induces migration and in vivo proliferation. (2008) *Cancer Research*. Under revision

Fan, Q-W, Cheng, C. K., Nicolaides, T. P., Knight, Z., Shokat, K. M., and Weiss, W. A. (2007) A dual PI3K $\alpha$ /mTOR inhibitor cooperates with blockade of EGFR in PTEN-mutant glioma, *Cancer Research*, 67: 7960-7965.

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Sala M, Varela M, Llovet JM, Bruix C, Bruix J. Diagnosis of hepatic nodules < 20 mm in cirrhosis. Prospective validation of the AASLD guidelines for Hepatocellular Carcinoma (HCC). *Hepatology* 2008; 47: 97-104.

Frankfurt, O, Licht JD, Tallman MS. Molecular Characterization of Acute Myeloid Leukemia and its Impact in Treatment. *Current Opinion in Oncology* 19: 635-49, 2007. PMID :17906465

Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J, Groszer M, Martinez-Diaz H, Rozengurt N, Thomas G, Liu X, Wu H. Genetic background controls tumor development in PTEN-deficient mice. *Cancer Res.* 2006; 66:6492-6.

Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Manickaratnam R, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, and Dmitrovsky E. Repression of cyclin D1 as a target for germ cell tumors. *International Journal of Oncology* 30:333-340, 2007.

Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Fu JF, Shi JY, Zhao WL, Li G, Pan Q, Li JM, Hu J, Shen ZX, Jin J, Chen FY, Chen SJ. MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders. *Leukemia* 2008; 22:660-663.

Germain, D., Frank, D.A. (2007) Targeting the cytoplasmic and nuclear functions of STAT3 for cancer therapy. *Clinical Cancer Research*, 13, 5665-5669.

Ghetu A, Corcoran C, Cerchietti L, Bardwell V, Melnick A, and Privé GG. Structure of a BCoR corepressor peptide in complex with the BCL6 BTB domain dimer. 2008. *Molecular Cell*. 29 (3) pp:384-391.

Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S, Enver T, Hildebrandt G, Zelent A. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. *Blood*, 111(4): 2374-7, 2008.

Grimmer, M., and Weiss, W.A. (2008) BMPs oppose Math1 in cerebellar development and in medulloblastoma. *Genes & Dev*, 22:693-699.

Gupta, P., L. Emdad, I.V. Lebedeva, D. Sarkar, P. Dent, D.T. Curiel, J. Settleman and P.B. Fisher. Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. *J. Cell. Physiol.* in press, 2008. (PMID: 18270968).

Guzman, ML, Rossi, RM, Neelakantan, S, Li, S, Corbett, C, Hassane, DC, Becker, MW, Bennett, J, Sullivan, E, Lachowicz, JL, Sweeney, CJ, Matthews, W, Carroll, M, Crooks, PA, and Jordan, CT (2007). An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood*, 110(13): 4427-35.

Hassane, DC, Guzman, ML, Corbett, C, Li, X, Abboud, R, Young, F, Liesveld, JL, Carroll, M, and Jordan, CT (2008). Discovery of Agents that Eradicate Leukemia Stem Cells Using an In Silico Screen of Public Gene Expression Data. *Blood*, in press.

Ishii, Y., Pirkmaier, A., Alvarez, J.V., Frank, D.A., Keselman, I., Logothetis, D., Mandeli, J., O'Connell, M.J., Waxman, S., Germain, D. (2006) Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. *J Natl Cancer Inst.* 2006 Sep 6;98(17):1238-47.

Ishii, Y., Waxman, S., Germain, D. (2007) Targeting the Ubiquitin-proteasome Pathway in Cancer Therapy, *Anti-cancer agents in Medicinal Chemistry*, 3, 369-365.

Ishii, Y., Waxman, S., Germain, D. (2008) Tamoxifen stimulates the growth of cyclin D1 overexpressing breast cancer cells by promoting the activation of STAT3. *Cancer Research*, 68 (3), 852.

Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. *Cancer Res.* 2007 67:6083-91.

Jing YK, Waxman S. The design of selective and non-selective combination therapy for acute promyelocytic leukemia. *Curr Top Microbiol Immunol.* 313:245-69, 2007.

Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Benzeno S, Lee JS, Schwartz M, Thung S, Fiel MI, Yea S, Banck M, Zimran E, Thorgeirsson S, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman S. Downregulation of KLF6 is an Early Event in Hepatocarcinogenesis, and Stimulates Proliferation while Reducing Differentiation. *J Hepatology* 2007;46:645-54.

Lebedeva, I.V., Z.-z. Su, L. Emdad, A. Kolomeyer, D. Sarkar, S. Kitada, S. Waxman, J.C. Reed and P.B. Fisher. Targeted inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. *Oncogene*, 26: 733-744, 2007. (PMID: 16924242)

Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. *Cancer Cell.* 2006;9:367-78.

Levy, D., Adamovich, Y, Reuven, N., and Shaul, Y. (2007). The Yes-Associated Protein1(YAP1) ptabilizes p73 by binding p73 and preventing Itch-mediated ubiquitination. *Cell Death and Differentiation*. 14(4):743-51.

Levy, D., Adamovich, Y, Reuven, N., and Shaul, Y. (2008). Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. *Mol Cell* 29:350-361.

Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn M. The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, prevent lung cancer induced by vinyl carbamate in A/J mice. *Cancer Res* 67:2414-2419, 2007.

Liby K, Black DD, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble G, Lamph W, Sporn TA, Dmitrovsky E, Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methylamide are significantly more potent than erlotinib for prevention of lung carcinogenesis in A/J mice. *Mol Cancer Ther* (in press).

Llovet, JM , Di Bisceglie A, J Bruix J, Kramer B, Lencioni R, Zhu A, Sherman M, Schwartz M, Lotze M, Talwalkar J, and Gores GJ on behalf of Panel of Experts in HCC. Design and endpoints of clinical trials in HCC. *Journal of Nacional Cancer Institutes* 2008 (in press).

Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. *Journal of Hepatology*, 2008 (in press).

Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. *Hepatology* 2008 (in press).

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Cosme A, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten T, Galle P, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J, for the SHARP Investigators Study Group\*. Sorafenib in advanced hepatocellular carcinoma. *New England Journal of Medicine* 2008; (in press).

Ma Y, Feng Q, Pitha-Rowe I, Kitareewan S, and Dmitrovsky E. Gene profiling uncovers retinoid target genes. *Cancer Genomics Proteomics* (Edited by Paul B. Fisher, Humana Press) pp. 101-121 2007.

Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MRM, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretta G, Pandolfi PP. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. *Science* 316:860-866, 2007.

Mann KK, Colombo M, and WH Miller Jr. Arsenic trioxide decreases Akt protein in a caspase-dependent manner. *Molecular Cancer Therapeutics*, in press, 2008.

Marango J, Shimoyama M, Nishio H, Meyer JA, Min D-J, Sirulnik, Martinez- Martinez Y, Chesi M, Bergsagel PL, Zhou M-M, Waxman S, Leibovitch BA, Walsh MJ, Licht JD. The MMSET Protein is a Histone Methyltransferase with Characteristics of a Transcriptional Co-repressor. *Blood*, 111:3145-54, 2008. PMID: 18156491.

Newell P, Villanueva A, Friedman S, Koike K, and Llovet JM. Experimental models in hepatocellular carcinoma. *Journal of Hepatology*, 2008;48:858-79.

Persson, A., Fan, Q-W., Phillips, J., and Weiss, W.A. (2007) Glioma. In Gilman, S. Editor: *Neurobiology of Disease*. Elsevier, San Diego, CA: pp. 433-444.

Petrie K and Zelent A. AML1-ETO, a promiscuous fusion oncoprotein. *Blood*, 109:4109-4110, 2007.

Petrie K, Guidez F, Zhu J, Owen G, Chew YP, Waxman S, Licht J, Mitternacht S, Zelent A. Retinoblastoma protein interacts with and enhances activity of the leukemia associated PLZF transcriptional repressor. *In Press- Oncogene*, 2008.

Petrie K, Guidez F, Zhu J, Owen G, Chew YP, Waxman S, Licht J, Mitternacht S and Zelent A. Interaction of retinoblastoma protein with the leukemia associated PLZF protein potentiates its ability to repress transcription. *Oncogene*, in press.

Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B-cells. *In revision, Blood*.

Pan Q, Zhu YJ, Gu BW, Cai X, Bai XT, Yun HY, Zhu J, Chen B, Weng L, Chen Z, Xue YQ, Chen SJ. A new fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation. *Oncogene* 2007; [Epub ahead of print]

Ranganathan AC, Ohja S, Kourtidis A, Conklin DS, and Aguirre-Ghiso JA. Dual function of PERK in tumor cell growth arrest and survival. *Cancer Res* (2008);68(9):1-9.

Rice, KL, Hormache I, Licht JD. Epigenetic Regulation of Normal and Malignant Hematopoiesis. *Oncogene* 26: 6697-6714, 2007. PMID :17934479

Sarkar, D., E.-S. Park, G.N. Barber and P. B. Fisher. Activation of double-stranded RNA-dependent protein kinase (PKR), a new pathway by which human polynucleotide phosphorylase (hPNPaseold-35) induces apoptosis. *Cancer Res.*, 67: 7948-7953, 2007. (PMID: 17804700).

Sarkar, D. and P.B. Fisher. Age-associated inflammation. In: *Encyclopedia of Cancer* 2, M. Schwab (Ed.) Springer-Verlag, in press, 2008.

Schroeder CP, Kadara H, Lotan D, Woo JK, Lee HY, Hong WK, Lotan R. Involvement of Mitochondria and Akt-Signaling Pathway in Augmented Apoptosis Induced by a Combination of Low Doses of Celecoxib and 4HPR in Premalignant Human Bronchial Epithelial Cells. *Cancer Res.* 2006 Oct 1;66(19):9762-70. PMID: 17018636.

Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Martignetti J, Marsh W, Llovet JM. Liver Transplantation for hepatocellular carcinoma: extended indications based on molecular markers. *Journal of Hepatology* 2008 (in press).

Sequeira SJ, Ranganathan AC, Adam AP, Iglesias BV, Farias EF, and Aguirre-Ghiso JA. Inhibition of Proliferation by PERK Regulates Mammary Acinar Morphogenesis and Tumor Formation. *PLoS ONE*. (2007) Jul18;2:e615.

Shah S, Blumen S, Pitha-Rowe I, Kitareewan S, Feng Q, Dmitrovsky E. UBE1L represses PML/RAR $\alpha$  by targeting the PML domain for ISG15ylation. *Mol Cancer Ther* (in press).

Silber, J., Lim, D. A., Petritsch, D., Maunakea, A. K., Persson, A., Yu, M., Vandenberg, S., Ginzinger, D., James, C. D., Costello, J. F., Weiss, W. A., Bergers, G., Alvarez-Buylla, A., and Hodgson, J. G. miR-124a and miR-137 induce differentiation of postnatal neural progenitor cells and glioma stem cells. *BMC Medicine*, In-Press.

Steinbrecher, K., E. Harmel-Laws, R. Sitcheran, and A. Baldwin (2008). Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. *J. Immunol.* 180, 2588-2599.

Sun XJ, Xu PF, Zhou T, Hu M, Fu CT, Zhang Y, Jin Y, Chen Y, Chen SJ, Huang QH, Liu TX, Chen Z. Genome-wide survey and development expression mapping of zebrafish SET domain-containing genes. *PLoS ONE* 2008; 3: e1499.

Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lotan D, and Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. *J Natl Cancer Inst.* 2007 Nov 21;99(22):1668-82. PMID: 18000218.

Tsvetkov, P., Asher, G., Paz, A., Reuven, N., Sussman, J.L., Silman, I. and Shaul, Y. (2008). Operational Definition of Intrinsically Unstructured Protein Sequences Based on Susceptibility to the 20S Proteasome. *PROTEINS: Structure, Function, and Bioinformatics.* 70:1357-1366.

Villanueva A, Newell P, Chiang D, Friedman S, Llovet JM. Genes and signaling pathways involved in the pathogenesis of HCC. *Sem Liv Dis* 2007 2007; 27: 55-76.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. *Cancer Cell.* 2007; 11:555-69.

Wang, J., H. An, M. Mayo, A. Baldwin, and W. Yarbrough (2007). LZAP, a putative tumor suppressor, selectively inhibits NF- $\kappa$ B. *Cancer Cell* 12, 239-251. in drug response and disease etiology. *FEBS J.*, In press, 2008.

Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yang XJ, Xu F, Wang BS, Mao JH, Shen ZY, Chen SJ, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. *PNAS* 2008; 105: 4826-4831.

Wang LG, Johnson EM, Kinoshita Y, Babb J, Buckley M, Liebes L, Melamed J, Liu X-M\*, Kurek R, Ossowski L, and Ferrari AC. Androgen receptor over- expression in advanced prostate cancer linked to Pura loss from a novel repressor complex (2008) *Cancer Research*. April 15. In Press

Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. *Proc Natl Acad Sci U S A*. 2006; 103:1480-5.

Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood* 2008; 111:2505-2515.

Weiss, W. A, Taylor, S. S., and Shokat, K. M. (2007) Recognizing and exploiting differences between RNAi and small molecule inhibitors. *Nature Chemical Biology*, 3: 739-744.

Witcher M, Pettersson F, Padovani A, Summers-Deluca L, Dupéré-Richer, D, Baldwin AS, Miller WH Jr. Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. *Nucleic Acids Research*, 2008, 36:435-443, 2008.

Wurmbach E, Chen Y, Khitrov G, Roayaie S, Fiel I, Schwartz M, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide profiles of dysplasia and HCC in HCV -cirrhotic patients. *Hepatology*, 2007, 45: 938-47.

Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR. Identification of prostate cancer modifier pathways using parental strain expression mapping. *Proc Natl Acad Sci U S A*. 2007; 104:17771-6.

Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shirasawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman S. Ras Promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. *Gastroenterology* 2008 (in press).

Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, So CW. Recruitment of RXR by homotetrameric RAR $\alpha$  fusion proteins is essential for transformation. *Cancer Cell* 12:36-51, 2007.

Zelent A, Petric K, Boix-Chornet M, Melnick A, Waxman S, Gore S. De-repression in the Desert: Report of the Third Biennial Workshop on Clinical Translation of Epigenetics in Cancer Therapy, Phoenix, Arizona. *Cancer Res*, in press.

Zhang SJ, Ma LH, Huang QH, Li G, Gu BW, Gao XD, Shi JX, Wang YY, Gao L, Cai X, Ren RB, Zhu J, Chen Z, Chen SJ. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. PNAS 2008;105:2076-2081.

Zhao GS, Liu C, Wang R, Song DD, Wang X, Lou HX and Jing YK. The synthesis of  $\alpha$ ,  $\beta$ -unsaturated carbonyl derivatives with the ability to inhibit both glutathione S-transferase P1-1 activity and the proliferation of leukemia cells. Bioorganic and Medicinal Chemistry, 15:2701-7, 2007.

Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, Shen ZX, Chen Z, Janin A, Chen SJ. PRDM1/BLIMP-1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 2008. [Epub ahead of print]

Zhou GB, Chen SJ, Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in genomic era. Acta Pharmacologica Sinica 2007; 28: 1434-1449.

Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007; 109:3441-3450.

Zhou GB, Chen SJ, Wang ZY, Chen Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Research 2007; 17: 274-276.

98 Publications